Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

NCT04616560 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

77

Enrollment

NIH

Sponsor class

Stopped Other - Stage 1 has met accrual

Conditions

Osteosarcoma
Recurrent Osteosarcoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
BIOLOGICAL: Trastuzumab Deruxtecan

Sponsor

National Cancer Institute (NCI)